Lecanemab (Leqembi; Esai Co. Ltd. and Biogen) is an intravenously administered anti-amyloid beta (Aβ) protofibril antibody indicated for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.